Hajar IHLAL

Dr. Hajar IHLAL


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2025 in neurogenetics
Verified
Journal Article
Closed access
PDF file
AOAmal Ouskri
Amal Ouskri
HIHajar IHLAL
Hajar IHLAL
ZEZaid En-Nasery
Zaid En-Nasery
SCSanae Chaouki
Sanae Chaouki
LBLaila Bouguenouch
Laila Bouguenouch
SJSylvie Jaillard
Sylvie Jaillard

4 September 2026 in Frontiers in Bioscience-Scholar
Verified
Journal Article
Open access
PDF file
IFIkram EL Fazazi
Ikram EL Fazazi
HIHajar IHLAL
Hajar IHLAL
AOAmal Ouskri
Amal Ouskri
SNSamira Nmer
Samira Nmer
AWAngela Washenko
Angela Washenko
MEMohammed El-Azami-El-Idrissi
Mohammed El-Azami-El-Idrissi
Multiple myeloma (MM) is a biologically and clinically heterogeneous plasma cell malignancy characterized by clonal expansion in the bone marrow and a highly variable clinical course. Despite major therapeutic advances, MM remains incurable, largely due to the associated genomic complexity, clonal evolution, and the emergence of treatment resistance. In this context, next-generation sequencing (NGS) has emerged as a transformative tool for improving disease characterization, risk stratification, and clinical management. This review summarizes current evidence on the application of NGS technologies, including whole-exome sequencing, whole-genome sequencing, and targeted gene panels—in the diagnosis, prognostic assessment, and monitoring of MM. Genomic profiling has consistently revealed recurrent alterations in key driver genes, copy number abnormalities, and structural variants that underlie disease heterogeneity and influence clinical outcomes. In addition to baseline characterization, NGS enables high-resolution analysis of clonal architecture and evolution, offering critical insights into mechanisms of relapse and therapeutic resistance. Importantly, NGS-based assessment of minimal residual disease (MRD) has demonstrated superior sensitivity compared with conventional techniques, providing a powerful prognostic marker and a promising tool for treatment monitoring and response-adapted strategies. Indeed, by integrating genomic and MRD data, NGS supports a more precise and dynamic approach to patient management. Overall, the growing body of evidence highlights NGS as a central component of precision medicine in multiple myeloma. Continued efforts toward standardization, validation of emerging biomarkers, and clinical implementation of sequencing-guided strategies are expected to enhance personalized treatment further and improve patient outcomes.

17 July 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
IFIkram EL FAZAZI
Ikram EL FAZAZI
HIHajar IHLAL
Hajar IHLAL
MAMeriame Abbassi
Meriame Abbassi
MAMohamed Ahakoud
Mohamed Ahakoud
SNSamira Nmer
Samira Nmer
MEMohammed El-Azami El-Idrissi
Mohammed El-Azami El-Idrissi
Multiple myeloma (MM) is an incurable, diverse cancer in which abnormal plasma cells produce and release monoclonal immunoglobulin (Ig), also known as monoclonal protein or M protein. MM is always preceded by monoclonal gammaglobulinemia of unknown significance (MGUS) and smoldering multiple myeloma (SMM). Diagnosis of MM is made from a bone marrow sample, which involves analysis of the appearance of plasma cells. Quantification of CD138+ plasma cells in core biopsies is performed using techniques such as immunohistochemistry, flow cytometry, fluorescence in situ hybridization (FISH) and conventional cytogenetics. Urinalysis includes total protein by immunofixation and 24-hour urine by serum protein electrophoresis. FISH probes should detect the presence of at least del 13, del 17p, t(4;14), t(11;14), t(14;16), and 1q21 amplifications. Indeed, next-generation sequencing (NGS) has become an increasingly important tool in the diagnosis and treatment of MM. It can be used to identify genetic mutations, copy number changes, and clonal structures to help determine disease prognosis and treatment strategies. NGS can identify subclonal populations of cancer cells that are resistant to therapy and may lead to disease relapse, and can be used to identify potential targets for personalized therapy. For example, NGS can identify mutations in genes involved in drug resistance, enabling the selection of drugs that may be more effective in treating a patient's cancer. This systematic review analyzes 182 papers to determine the position and role of NGS in the diagnosis of MM. We first analyze the platforms and sample types used in the selected studies, and then start discussing the results.

26 January 2026 in neurogenetics
Verified
Journal Article
Closed access
AOAmal Ouskri
Amal Ouskri
HIHajar IHLAL
Hajar IHLAL
OLOumayma Lahjouji
Oumayma Lahjouji
NBNizar Bouardi
Nizar Bouardi
MAMohammed Ahakoud
Mohammed Ahakoud
PBPascale Benlian
Pascale Benlian